TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Patient is at least 18 years of age.~2. Naive or recurrent patients with low grade (LG), non-invasive Upper Tract Urothelial Carcinoma (UTUC) in the pyelocalyceal system.~3. Patient has at least one (1) measurable papillary LG tumor, evaluated visually, ≤ 15 mm. The largest lesion should not exceed 15mm.~4. Biopsy taken from one or more tumors located above the ureteropelvic junction (UPJ) showing LG urothelial carcinoma. Diagnosed not more than 2 months prior to the screening.~5. Patient should have at least one remaining papillary LG tumor evaluated visually with a diameter of at least 5 mm.~6. Wash urine cytology sampled from the pyelocalyceal system documenting the absence of High Grade (HG) urothelial cancer, diagnosed not more than 2 months prior to the screening.~7. Patient with bilateral LG UTUC may be enrolled if at least one side meets the inclusion criteria for the trial and if the other kidney does not require further treatments (The other kidney can be treated prior to the beginning of the study).~Main Exclusion Criteria:~1. Patient received Bacille de Calmette et Guérin (BCG) treatment for Urothelial carcinoma (UC) during the 6 months prior to Visit 1.~2. The patient has untreated concurrent urothelial cancer in other locations other than the target area (unless treated during screening)~3. Carcinoma in situ (CIS) in the past in the urinary tract.~4. Patient has a history of invasive urothelial carcinoma in the urinary tract during the past 5 (Five) years.~5. Patient has a history of high grade papillary urothelial carcinoma in the urinary tract during the past 2 (Two) years.~6. Patient is actively being treated or intends to be treated with systemic chemotherapy during the duration of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UGN-101 instillations (Type: EXPERIMENTAL): The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, maximum dose is 15ml. 6 once weekly intravesical instillations for the ablation treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of one of the following~  * Newly diagnosed de novo acute myeloid leukemia (AML)~ * AML secondary to myelodysplastic syndromes (MDS)~ * AML secondary to exposure to leukemogenic therapy or agents with primary malignancy in remission for at least 2 years~* Bone marrow blasts \>30%~* Age ≥ 65 years~* Easter Cooperative Oncology Group (ECOG) 0-2~Exclusion Criteria:~* Previous cytotoxic or biologic treatment for AML (except hydroxyurea)~* Previous treatment with azacitidine, decitabine or cytarabine~* Prior use of targeted therapy agents (e.g., FLT3 inhibitors, other kinase inhibitors)~* AML French American British subtype (FAB M3)~* AML associated with inv(16), t(8;21), t(16;16), t(15:17), or t(9;22) karyotypes~* Prior bone marrow or stem cell transplantation~* Candidate for allogeneic bone marrow or stem cell transplant~* Diagnosis of malignant disease within the previous 12 months (excluding base cell carcinoma, in-situ carcinoma of the cervix or breast or other local malignancy excised or irradiated with a high probability of cure)~* Malignant hepatic tumors~* Uncontrolled systemic infection~* Active viral infection with Human Immunodeficiency Virus (HIV) or Hepatitis type B or C~* Use of any experimental drug or therapy within 28 days prior to Day 1

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azacitidine (Type: EXPERIMENTAL): Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
- Conventional Care Regimen (Type: ACTIVE_COMPARATOR): Conventional Care Regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor.~* Requiring hormonal treatment.~* Postmenopausal women (woman who has stopped having menstrual periods)~Exclusion Criteria:~* Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced BC.~* Treatment with more than one previous regimen of endocrine therapy for advanced BC.~* An existing condition that prevents compliance.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Fulvestrant 250 mg (intramuscular injection 250 mg)
- 2 (Type: EXPERIMENTAL): Fulvestrant 250 mg (+ 250 mg loading regimen)
- 3 (Type: EXPERIMENTAL): Fulvestrant 500 mg (intramuscular injection 500 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs~Exclusion Criteria:~* Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the study period~* Patients who are at a significantly high risk for bleeding or thromboembolism~* Patients who are receiving another antithrombotic therapy and are unable to suspend the therapy~* Patients who have evidence of hepatic function test abnormalities

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SRI 15mg (15 mL/min ≤ CLCR < 20mL/min) (Type: EXPERIMENTAL): Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
- MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min) (Type: EXPERIMENTAL): Mild Renal Impairment group orally administered 30mg DU-176b once daily for 14 days.
- Fondaparinux (20 mL/min ≤ CLCR < 30mL/min) (Type: ACTIVE_COMPARATOR): Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.
- SRI 15mg (20 mL/min ≤ CLCR < 30mL/min) (Type: EXPERIMENTAL): Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib in Systemic Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Adults with refractory diffuse or limited SSc and any or all of the following: Progressive cutaneous fibrosis, Interstitial lung disease, Pulmonary arterial hypertension, Digital ulcerations.~Exclusion Criteria:~Uncontrolled congestive heart failure, hypertension, or coronary artery disease.~HIV, hepatitis B, and/or hepatitis C infection. Serious infection within the past month. Significant hematologic, renal, or hepatic abnormalities. Concurrent use of intravenous immunoglobulin or cyclophosphamide within 4 weeks of the first treatment dose.~Concurrent use of a biologic agent (ie. etanercept, infliximab, adalimumab, abatacept) within 8 weeks of the first treatment dose (6 months for rituximab).~Women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate (Type: EXPERIMENTAL): 100 mg daily and increase by 100mg daily every 2 weeks to a maximum of 400 mg daily as tolerated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MyDiaText Text Messaging Intervention for Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 1 diabetes for more than 1 year~* HbA1c greater than or equal to 8% but less than 14%.~* Have been seen in diabetes clinic in the last 6 months~* Owns a personal mobile device with unlimited text messaging plan~Exclusion Criteria:~* Non-English speaking~* Significant cognitive disability or major organ illness~* Hemolytic anemia

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): This group will receive the intervention for 6 months. The intervention will consist of daily text messages sent to the subject's personal mobile device in addition to the usual standard care. Subjects will be incentivized to respond to text messages via a financial reward lottery system. Previously developed text messages based on the ADA behavior goals will be used for this intervention.
- Control (Type: NO_INTERVENTION): This group will receive the usual standard of care for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. men and woman age 18 and older;~2. Not hospitalized;~3. Has recently tested SARS-CoV-2 (COVID-19 virus) positive.~4. Currently symptomatic with one or more of one or more of the following symptoms: fever, cough, myalgia, mild dyspnea, diarrhea, vomiting, anosmia (inability to smell), ageusia (inability to taste), sore throat.~5. Able to provide informed consent.~Exclusion Criteria:~1. Illness severe enough to require hospitalization or already meeting study's primary endpoint for clinical worsening.~2. Unstable medical comorbidities including, but not limited to: Severe underlying lung disease (COPD on home oxygen, interstitial lung disease, pulmonary hypertension), decompensated cirrhosis, Congestive heart failure (stage 3 or 4 per patient report and/or medical records).~3. Immunocompromised (solid organ transplant, BMT, AIDS, on biologics and/or high dose steroids (\>20mg prednisone per day)~4. Unable to provide informed consent (eg moderate-severe dementia diagnosis)~5. Unable to perform the study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluvoxamine (Type: EXPERIMENTAL): Start fluvoxamine 100mg capsules, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in the RCT for approximately 15 days.
- Placebo (Type: PLACEBO_COMPARATOR): Start placebo one capsule, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in RCT for approximately 15 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vestibular Rehabilitation and Dizziness in Geriatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must be at least 60 years of age, seeking medical care due to dizziness and have normal vestibular function based on results of the clinical examination, rotary chair and/or caloric tests.~Exclusion Criteria:~Abnormal vestibular function based on results of clinical examination, rotary chair and/or caloric tests.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vestibular Rehabilitation (Type: EXPERIMENTAL): vestibular exercises plus standard balance and gait exercises
- Placebo (Type: PLACEBO_COMPARATOR): placebo exercises plus standard balance and gait exercises

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Effect of PAP on Energy and Vitality in Mild OSA Patients: The Merge Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Study Inclusion Criteria~* Aged ≥ 18 and ≤ 80~* Ability and willingness to provide written informed consent~* AHI ≤ 15 as per AASM 2007 scoring criteria~* Ability to tolerate a CPAP one hour long run in test~Exclusion Criteria:~* The presence of unstable cardiac disease~* Inability to give fully informed consent~* Supplemental oxygen~* Secondary sleep pathology e.g. Periodic Limb Movement Syndrome, Narcolepsy, Circadian Disorder, obesity hypoventilation syndrome~* ESS ≥ 15, or concerns about sleepy driving from physician/ sleep lab staff~* BMI ≥ 40

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Continous Positive Airway Pressure (Type: ACTIVE_COMPARATOR): Participants in this group will use CPAP therapy, nightly, for the 3 month duration of the trial
- Control Group (Type: PLACEBO_COMPARATOR): Participants will receive standard care (Sleep hygiene counseling) during the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reversing the Effects of 2% Lidocaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Students of the Dalhousie University Dental Clinic who are:~* Age 18 and over~* Capable of providing informed consent~Exclusion Criteria:~* Subjects with a medical history that contraindicates the use of epinephrine.~* Subjects who have taken an opioid or an opioid-like analgesic within 24 hours of the anesthesia session.~* Pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Phentolamine mesylate (Type: EXPERIMENTAL): Once anesthesia is confirmed, subjects in the Phentolamine mesylate group will receive 1 injection of 1ml of a solution containing 0.24 mg of phentolamine mesylate in the same site that was previously anaesthetized (not as a part of the study).
- Water (Type: PLACEBO_COMPARATOR): Once anaesthesia is confined, the subjects in the water group will receive 1 injection of 1 ml of sterile physiological water in the same site that was previously anaesthetized (not as a part of the study).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botox Injection in Treatment of Chronic Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed and written consent~* Chronic migraine with or without aura defined in International Classification of Headache Disorders (ICHD)-3 criteria~* Failed at least 3 oral migraine prophylactic treatments~* Duration of migraine at least 1 year before inclusion~* Start of migraine before participant turned 50 years~* Participant can make a distinction between migraine and other types of headache~Exclusion Criteria:~* If the criteria for medication-overuse headache (MOH) is fulfilled~* Heart or lung disease~* Any kind of systematic or local disease or illness that may significantly increase the risk of complications for the procedure related to injection~* Psychiatric illness that hinders participation in the study~* Known pregnancy or breast feeding~* Inadequate use of contraceptives~* Overuse or abuse of opioids~* Abuse of medications, narcotics or alcohol~* Anomalies which hinder or impede the used method of injection~* Allergy or any other hypersensitivity reactions against marcain, lidocaine, xylocain or adrenalin, botulinum toxin type A, Botox or any of it's constituents or any other related medication~* Treatment with medication that can interact with botulinum toxin type A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Botulinum Toxin (Type: EXPERIMENTAL): The patients will be injected with 25 IU of Botulinum Toxin Type A towards both the right and left sphenopalatine ganglion, a total of 50 IU.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mobile Insulin Titration Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Initiating long-acting insulin treatment or initiating the titration of long-acting insulin treatment~* Speaks English or Spanish~* Hemoglobin A1c \> or = 8%~* Able and willing to inject insulin~* Able and willing to provide informed consent~Exclusion Criteria:~* Short-acting insulin treatment~* Systemic glucocorticoids~* Sustained elevated serum creatinine \> or = 1.5 mg/dL for men and \> or = 1.4 mg/dL for women~* Hypoglycemia unawareness~* Type 1 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Mobile Insulin Titration Intervention (Type: EXPERIMENTAL): Mobile Insulin Titration Intervention (MITI) arm patients will relay their fasting blood glucose levels to the study staff via text message. The patient will receive insulin titration instructions through a weekly phone call with a diabetes nurse.
- Current Best Practice (Type: NO_INTERVENTION): Current Best Practice (CBP) arm patients will be treated according to the current best practice of insulin titration. They will attend scheduled clinic visits during which the provider will review their blood glucose logs and provide insulin titration instructions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Approach for Controlling Hemostasis During Canal Treatment: a Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* tooth affected by irreversible pulpitis, single-rooted teeth associated with healthy periodontium, physiologic sulcus depth (\<3 mm), and absence of bleeding on probing of the involved teeth.~Exclusion Criteria:~* patients with systemic diseases using anticoagulants, antibiotics, or anti-inflammatory therapies in the last 30 days, patients with allergy to sulfur in any form, and pregnancy.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- HYBENX® (Type: EXPERIMENTAL): 1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged greater or equal to 12 years~* Intra-abdominal infection documented by laparotomy or laparoscopy or percutaneous aspiration within 24 hours prior to screening~* Presence of at least three of the following five indicators consistent with intra-abdominal infections (Fever, leucocytosis, abdominal symptoms, abdominal signs, radiological evaluation)~* Written informed consent obtained~Exclusion Criteria:~* Rapidly progressive illness or critically ill subjects~* Pregnant or lactating women, or women of childbearing potential not using an effective method of contraception.~* Treatment with a presumably effective systemic antimicrobial agent for \>24 hours within a 72 hour period prior to study entry unless the subject did not sufficiently respond to the treatment (as judged by the investigator)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete